Cell Therapeutics, Inc. (CTI) Readies Pixuvri® European Launch and Start of ... MSN Money The European Medicines Agency's (the "EMA") Committee for Medicinal Products for Human Use has accepted PIX306, CTI's ongoing randomized controlled phase III clinical trial, which compares Pixuvri-rituximab to gemcitabine-rituximab in patients who ... Cell Therapeutics Management Discusses Q2 2012 Results - Earnings Call ... |
